Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2026 02:00 ET | Source: Greywolf Therapeutics

Greywolf Therapeutics reports durable clinical responses with first-in-class oral ERAP1 inhibitor GRWD5769 across six solid tumor types

First-in-class oral ERAP1 inhibitor shows 13–36% ORR across 6 solid tumor types in anti-PD-1 resistant patients